« Back
Home /
Rucaparib

Rucaparib

Item no.	HY-10617A-50mg
Manufacturer	MedChem Express
CASRN	283173-50-2
Amount	50 mg
Quantity options	100 mg 10 mM/1 mL 10 mg 1 mg 200 mg 50 mg 5 mg
Category	Inhibitors & Compound Libraries Small Molecules
Type	Inhibitors
Specific against	other
Purity	99.97
Citations	[1]Thomas HD, et al. Preclinical selection of a novel poly(ADP-ribose) polymerase inhibitor for clinical trial. Mol Cancer Ther, 2007, 6(3), 945-956.\|[2]Hunter JE, et al. NF-κB mediates radio-sensitization by the PARP-1 inhibitor, AG-014699. Oncogene, 2012, 31(2), 251-264.\|[3]Daniel RA, et al. Inhibition of poly(ADP-ribose) polymerase-1 enhances temozolomide and topotecan activity against childhood neuroblastoma. Clin Cancer Res, 2009, 15(4), 1241-1249.\|[4]Matt Shirley, et al. Rucaparib: A Review in Ovarian Cancer. Target Oncol. 2019 Apr;14(2):237-246.\|[5]J Murray, et al. Tumour cell retention of rucaparib, sustained PARP inhibition and efficacy of weekly as well as daily schedules. Br J Cancer. 2014 Apr 15;110(8):1977-84.\|[6]Jianneng Li, et al. Hexose-6-phosphate dehydrogenase blockade reverses prostate cancer drug resistance in xenograft models by glucocorticoid inactivation. Sci Transl Med. 2021 May 26;13(595):eabe8226. Aging. 2021 Jan 20;13(3):4242-4257.\|Am J Cancer Res. 2020 Aug 1;10(8):2649-2676.\|Am J Cancer Res. 2024 Jan 15;14(1):378-389.\|bioRxiv. 2023 Feb 6.\|bioRxiv. 2023 Feb 7.\|bioRxiv. 2024 Jul 10:2024.07.09.602803.\|bioRxiv. 2024 September 19.\|BMC Cancer. 2022 Mar 23;22(1):312.\|Cancers (Basel). 2024 Nov 5;16(22):3728.\|Clin Cancer Res. 2017 Feb 15;23(4):1001-1011. \|DNA Repair (Amst). 2019 Jan;73:64-70.\|Eur J Nucl Med Mol Imaging. 2024 Jul 18.\|FASEB J. 2022 Jul;36(7):e22418.\|Front Oncol. 2021 Jul 9;11:681441.\|Gene. 2020 Oct 30;759:145000.\|Genes Dis. 2023 Apr 12.\|Int J Mol Sci. 2020 Feb 11;21(4):1185.\|JCI Insight. 2023 Nov 8;8(21):e165268.\|Mol Cancer Ther. 2024 Jun 19.\|Nat Methods. 2023 Sep;20(9):1388-1399.\|Neoplasia. 2025 Mar 16:63:101152.\|Neurooncol Adv. 2023 Feb 10;5(1):vdad010.\|Patent. US20180263995A1.\|Patent. US20180362972A1.\|Research Square Preprint. 2024 Nov 06.\|Research Square Print. September 20th, 2022.\|Research Square Print. September 22nd, 2022.\|Sci Adv. 2022 Feb 18;8(7):eabl9794.\|Sci Immunol. 2024 Mar 15;9(93):eadj7238.\|Sci Transl Med. 2021 May 26;13(595):eabe8226.\|Talanta. 2018 Apr 1;180:127-132.\|Theranostics. 2020 Jul 25;10(21):9477-9494. \|Analyst. 2018 May 29;143(11):2501-2507.\|Biochem Biophys Res Commun. 28 September 2021.\|J Mol Med (Berl). 2019 Aug;97(8):1183-1193.\|Nat Cell Biol. 2024 Jul 12.\|Patent. US20200078369A1\|Patent. US20200129476A1\|PLoS One. 2024 Nov 1;19(11):e0308647.\|Sens Actuators B Chem. 2018 Nov 10; 273:1047-1053.\|Sens Actuators B Chem. 2018, 259: 565-572.\|J Med Chem. 2023 Mar 6.\|J Mol Med (Berl). 2019 Aug;97(8):1183-1193.
Smiles	FC1=CC2=C3C(CCNC2=O)=C(C4=CC=C(CNC)C=C4)NC3=C1
ECLASS 10.1	32160490
ECLASS 11.0	32160490
UNSPSC	12000000
Alias	AG014699,PF-01367338
Shipping Condition	Room temperature
Available
Manufacturer - Type	Reference compound
Manufacturer - Applications	Cancer-programmed cell death
Manufacturer - Targets	PARP
Shipping Temperature	Room Temperature
Storage Conditions	-20°C, 3 years; 4°C, 2 years (Powder)
Molecular Weight	323.36
Product Description	Rucaparib (AG014699) is an orally active, potent inhibitor of PARP proteins (PARP-1, PARP-2 and PARP-3) with a Ki of 1.4 nM for PARP1. Rucaparib is a modest hexose-6-phosphate dehydrogenase (H6PD) inhibitor. Rucaparib has the potential for castration-resistant prostate cancer (CRPC) research[1][2][3][4].
Manufacturer - Research Area	Cancer
Solubility	DMSO: 70 mg/mL (ultrasonic; warming; heat to 60°C)\|H2O: < 0.1 mg/mL (ultrasonic; warming; heat to 60°C)
Manufacturer - Pathway	Cell Cycle/DNA Damage; Epigenetics
Isoform	PARP1; PARP2; PARP3
Clinical information	Launched

Note: The presented information and documents (Manual, Product Datasheet, Safety Datasheet and Certificate of Analysis) correspond to our latest update and should serve for orientational purpose only. We do not guarantee the topicality. We would kindly ask you to make a request for specific requirements, if necessary.

All products are intended for research use only (RUO). Not for human, veterinary or therapeutic use.

Request Data Sheet

Request product datasheet

HY-10617A-50mg-safety-datasheet.pdf